Who is sponsoring NCT00208065?

NCT00208065 is sponsored by Clinvest.

What condition does NCT00208065 study?

NCT00208065 studies Migraine, Sinusitis.

What drugs are being tested in NCT00208065?

Interventions: almotriptan or pseudoephedrine.

What is the status of NCT00208065?

NCT00208065 is currently COMPLETED.

Last reviewed 2009-05-05 · How we verify

Evaluation of Histamine, CGRP and VIP as Biological Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers in Response to "Sinus" Symptoms

NCT00208065 Phase 4 COMPLETED

The primary objective of this study is to evaluate histamine, CGRP and VIP levels in saliva as biological markers for activation of trigeminal and parasympathetic nerve fibers in various clinical presentations of primary headaches compared to allergic rhinosinusitis and control populations.

Details

Lead sponsor	Clinvest
Phase	Phase 4
Status	COMPLETED
Enrolment	50
Start date	2004-05
Completion	2005-11

Conditions

Migraine
Sinusitis

Interventions

almotriptan or pseudoephedrine

Primary outcomes

Baseline histamine, CGRP and VIP levels in saliva of 5 groups of subjects (A-Control group, B-Rhinosinusitis, C-Migraine with early sinus symptoms, D-Migraine with late sinus symptoms, E-Migraine without sinus symptoms

Countries

United States